edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Basilea Pharmaceutica
Basilea Pharmaceutica is focused on treating infectious diseases; its marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA antibiotic). In late 2023, it expanded its pipeline to include fosmanogepix, BAL2062 and tonabacase. In January 2024, it acquired the preclinical LptA inhibitor antibiotics programme from Spexis.
Basilea Pharmaceutica — 12 videos in collection
Basilea Pharmaceutica is a Switzerland-based biotech specialising in the anti-fungal/anti-infective niche, where it has been able to commercialise via partnerships with large pharma. The company’s lead assets are Cresemba (or isavuconazole – an antifungal therapy) and Zevtera (or ceftobiprole – an antibiotic therapy). The company’s expanding portfolio includes preclinical assets and the recent antifungal Phase III-ready asset addition, Fosmanogepix.
Get access to the very latest content matched to your personal investment style.